Market Intelligence, Clinical Progress, and High-Purity Reagents for Antithrombotic & Hemostasis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD42b/GP1BA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD42b/GP1BA ECD-Fc Fusion Protein (HEK293, Native Glycosylation, >95% purity, <1EU/ug endotoxin). Essential for VWF A1 domain binding and shear-flow assays. | View GP1BA Products |
| Gene Delivery | CD42b/GP1BA Lentivirus Premade Particles (full-length ORF) for stable cell lines and conformational epitope preservation. | View GP1BA Products |
| Benchmark Ab | Anti-CD42b/GP1BA Reference Antibody (recombinant positive control) for competitive binding and platelet inhibition assays. | View GP1BA Products |
| Validator | CD42b/GP1BA siRNA Set for knockdown verification and specificity control. | View GP1BA Products |
| Related Target A | vWF (von Willebrand Factor) – primary physiological ligand for GPIb-IX-V complex. | View vWF Products |
| Related Target B | GP9 (CD42a) – essential complex partner for surface expression of GPIb-IX-V. | View GP9 Products |
| Related Target C | ADAMTS13 – VWF-cleaving protease that regulates GP1BA–VWF interaction dynamics under shear stress. | View ADAMTS13 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| vWF interaction blocking / shear‑dependent binding | HEK293 expressed ECD-Fc with native glycosylation preserves LRR mechanosensing domains; theoretical MW verified. |
| Cross‑species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence homology verified by mass spec. |
| Complex formation (GPIb‑IX‑V stability) | Co‑expression lentivirus systems available for GPIX (GP9) and GPV heteromeric complex assembly. |
| Polymorphism screening (e.g., Thr145Met) | Mutant recombinant proteins (Kozak variants) available for population pharmacology studies. |
| Lack of controls / false positives | Clinical benchmark antibodies included; validated siRNA for specificity; endotoxin <1 EU/µg. |
Live CD42b/GP1BA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD42b/GP1BA therapeutics is intensifying as developers seek antithrombotic agents with reduced bleeding risk compared to standard P2Y12 inhibitors or integrin αIIbβ3 blockers. While first‑generation approaches focused on VWF inhibition, the next wave of R&D is targeting direct GP1BA modulation to preserve physiological hemostasis while preventing pathological thrombosis. Emerging modalities include allosteric inhibitors and shear‑sensitive aptamers designed to act specifically in high‑shear arterial thrombosis without compromising low‑shear venous hemostasis. Major players (Sanofi, CSL Behring, AdvanceCOR) are shifting focus from broad‑spectrum antiplatelets to targeted vWF–GPIb axis inhibitors, aiming for high antithrombotic efficacy with near‑zero bleeding risk.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies / Fab | Sanofi, CSL Behring | Ischemic Stroke, TTP, Acute Coronary Syndrome (ACS) | Epitope mapping (need high‑purity ECD‑Fc truncations) & cross‑species binding for toxicology bridging. |
| Nanobody / VHH | Specialized Biotech | Thrombotic Thrombocytopenic Purpura (TTP) | High‑concentration stability test; VWF competition SPR. |
| Recombinant Fusion Proteins | AdvanceCOR (Revacept) | Atherothrombosis, ACS | Ligand blocking assay (need HEK293 glycosylated vWF) & mutant vs. WT selectivity. |
| Aptamers & Peptides | Various Biotechs | Ischemic Stroke, VTE, PCI Support | Shear‑dependent binding (microfluidic validation using lentivirus‑expressing cell lines) & structural stability. |